

# Prof. GÜNEŞ ESENDAĞLI

## Personal Information

Office Phone: [+90 312 305 4322](tel:+903123054322)

Office Phone: [+90 312 305 4413](tel:+903123054413)

Fax Phone: [+90 312 324 2009](tel:+903123242009)

Email: [gunese@hacettepe.edu.tr](mailto:gunese@hacettepe.edu.tr)

Web: <https://www.esendagilab.com>

## International Researcher IDs

ScholarID: kR\_HQHMAAAAJ

ORCID: 0000-0003-4865-2377

ScopusID: 24328713600

Yoksis Researcher ID: 27306

## Education Information

Doctorate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Kanser Enstitüsü Temel Onkoloji Anabilim Dalı, Turkey 2003 - 2007

Postgraduate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Kanser Enstitüsü Temel Onkoloji Anabilim Dalı, Turkey 2001 - 2003

Undergraduate, Istanbul University, Cerrahpaşa Tıp Fakültesi, Tıbbi Biyolojik Bilimler Bölümü, Turkey 1997 - 2001

## Foreign Languages

English, B2 Upper Intermediate

French, B1 Intermediate

## Dissertations

Doctorate, Kimyasal karsinogenezle oluşturulmuş meme tümör hücrelerinin CD40 ligand ile genetik modifikasyonu ve allojenik aşı preparatı olarak kullanılabilirliğinin değerlendirilmesi, Hacettepe Üniversitesi, Kanser Enstitüsü, Tümör Biyolojisi Ve İmmünolojisi (YI) (Tezli), 2007

Postgraduate, CD40 ligand (CD154) genin ökaryotik ekspresyon vektörüne klonlanması, Hacettepe Üniversitesi, Kanser Enstitüsü, Temel İmmünoloji (YI) (Tezli), 2003

## Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Microbiology and Clinical Microbiology, Immunology, Medical Biology, Life Sciences, Molecular Biology and Genetics, Molecular Biology of Cancer, Natural Sciences

## Academic Titles / Tasks

Professor, Hacettepe University, Kanser Enstitüsü, Temel Onkoloji A.B.D., 2018 - Continues

## Academic and Administrative Experience

Hacettepe Üniversitesi, Kanser Enstitüsü, 2012 - Continues

University Executive Board Member, Hacettepe University, 2017 - 2019

## Courses

TİM 601 - Temel İmmünoloji I, Postgraduate, 2017 - 2018

KBI 602-TEMEL İMMÜNOLOJİ VE TÜMÖR BİYOLOJİSİ II, Postgraduate, 2017 - 2018, 2016 - 2017

KBI 601-TEMEL İMMÜNOLOJİ VE TÜMÖR BİYOLOJİSİ I, Postgraduate, 2017 - 2018, 2016 - 2017

KBİ 701-TEMEL ONKOLOJİ LABORATUVAR TEKNİKLERİ, Doctorate, 2017 - 2018, 2016 - 2017

TİM 602 - Temel İmmünoloji II, Postgraduate, 2017 - 2018

KBİ 722 - TEMEL İMMÜNOLOJİ II, Doctorate, 2017 - 2018, 2016 - 2017

KBİ 721-TEMEL İMMÜNOLOJİ I, Doctorate, 2017 - 2018, 2016 - 2017

## Advising Theses

ESENDAĞLI G., The effect of inducible costimulatory ligand (İCOS-LG) expressing myeloid leukemia cells on helper T lymphocyte activation and exhaustion, Postgraduate, D.ÖZKAZANÇ(Student), 2015

ESENDAĞLI G., All-trans retinoik asit (ATRA) ve 1 $\alpha$ ,25-dihidroksivitamin D3 (vitamin D3) ile uyarılan akut miyeloid lösemi hücrelerinin T hücre yanıtları üzerine etkisi, Postgraduate, D.YÖYEN(Student), 2014

GÜÇ D., ESENDAĞLI G., Fibroblast-breast cancer cells' interaction and Chemerin expression, Doctorate, D.RAMA(Student), 2011

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer's disease**  
Tezel G., Uluturk S., REÇBER T., TİMUR S. S., NEMUTLU E., ESENDAĞLI G., GÜLBAĞ PINAR S., EROĞLU H.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024 (SCI-Expanded)
- II. **Folate Receptor  $\beta$  (FR $\beta$ ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles' Biodistribution in Cancer.**  
Goksen S., Varan G., Bilensoy E., Esendagli G.  
Molecular pharmaceutics, vol.21, no.9, pp.4688-4699, 2024 (SCI-Expanded)
- III. **An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles.**  
Tonbul H., Şahin A., Öztürk S. C., Ultav G., Tavukçuoğlu E., Akbaş S., Aktaş Y., Esendağlı G., Çapan Y.  
Journal of drug targeting, pp.1-10, 2024 (SCI-Expanded)
- IV. **Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia**  
Parveen M., KARAOSMANOĞLU B., SUCULARLI C., ÜNER A., TAŞKIRAN Z. E., ESENDAĞLI G.  
European Journal of Immunology, 2024 (SCI-Expanded)
- V. **Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination**  
Tavukcuoglu E., Yanik H., Parveen M., Uluturk S., DURUSU TANRIÖVER M., İNKAYA A. Ç., AKOVA M., ÜNAL S., ESENDAĞLI G.  
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- VI. **The Effect of Paclitaxel with a STAT3 Pathway Inhibitor on Metastasis in the Treatment of Triple**

## **Negative Breast Cancer**

DİNÇSOY A. B., GEDİKLİ E., ÖZTÜRK S. C., Nikshiqi E., Baris V. O., KARAKOÇ E., Muftuoğlu S., ESENDAĞLI G., ERDEM A.

ACTA PHYSIOLOGICA, pp.45, 2023 (SCI-Expanded)

- VII. **Immune checkpoint status and exhaustion-related phenotypes of CD8+ T cells from the tumor-draining regional lymph nodes in breast cancer**  
Yilmaz I., Tavukcuoğlu E., Horzum U., Yilmaz K. B., Akinci M., Gulcelik M. A., ORAL H. B., ESENDAĞLI G.  
Cancer Medicine, vol.12, no.24, pp.22196-22205, 2023 (SCI-Expanded)
- VIII. **Liver resection modulates hepatic chemokine levels in breast cancer**  
DİNÇER H. A., Horzum U., Kursunel M. A., Yoyen-Ermis D., Ermis E., ÖZOĞUL E., AKKAPULU N., ESENDAĞLI G., KARAKOÇ D.  
Surgery (United States), vol.174, no.2, pp.277-282, 2023 (SCI-Expanded)
- IX. **Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors**  
Anthiya S., ÖZTÜRK S. C., Yanik H., Tavukcuoğlu E., ŞAHİN A., Datta D., Charisse K., Álvarez D. M., Loza M. I., Calvo A., et al.  
Journal of Controlled Release, vol.357, pp.67-83, 2023 (SCI-Expanded)
- X. **The synthesis and anti-cancer efficacy of endoperoxide modified copper sulfide-ferritin nanocages as PDT and PTT agents**  
Kucukoflaz M., Ulusoy S., Korkmaz B., ÖZTÜRK S. C., AKYOL M., Hayta S. B., Goze O. F., ESENDAĞLI G., SÖZMEN F.  
Journal of Nanoparticle Research, vol.25, no.4, 2023 (SCI-Expanded)
- XI. **A positive feedback loop driven by fibronectin and IL-1 $\beta$  sustains the inflammatory microenvironment in breast cancer**  
TUNALI G., Yanik H., ÖZTÜRK S. C., DEMİRKOL CANLI S., Efthymiou G., Yilmaz K. B., Van Obberghen-Schilling E., ESENDAĞLI G.  
Breast cancer research : BCR, vol.25, no.1, pp.27, 2023 (SCI-Expanded)
- XII. **A novel combination for the treatment of small cell lung cancer: Active targeted irinotecan and static co-loaded PLGA nanoparticles**  
Arslan F. B., ÖZTÜRK K., Tavukcuoğlu E., ÖZTÜRK S. C., ESENDAĞLI G., ÇALIŞ S.  
International Journal of Pharmaceutics, vol.632, 2023 (SCI-Expanded)
- XIII. **Effects of Particle Geometry for PLGA-Based Nanoparticles: Preparation and In Vitro/In Vivo Evaluation**  
Kaplan M., ÖZTÜRK K., ÖZTÜRK S. C., Tavukcuoğlu E., ESENDAĞLI G., ÇALIŞ S.  
Pharmaceutics, vol.15, no.1, 2023 (SCI-Expanded)
- XIV. **Characterization of serum extracellular vesicles and their differential level of miR-197-3p in familial Mediterranean fever patients**  
Tavukcuoğlu Z., AKKAYA ULUM Z. Y., YERSAL N., Horzum U., AKBABA T. H., KARADAĞ Ö., ESENDAĞLI G., KORKUSUZ P., ÖZEN S., Balci-Peynircioğlu B.  
Nucleosides, Nucleotides and Nucleic Acids, 2023 (SCI-Expanded)
- XV. **Pro-fibrogenic and adipogenic aspects of chronic muscle degeneration are contributed by distinct stromal cell subpopulations**  
ÖZDEMİR SAKA C., Akçay D., Yöyen-Ermiş D., Taşkıran E. Z., Soylu-Kucharz R., ESENDAĞLI G., KOCAEFE Y. Ç.  
PloS one, vol.18, no.7, 2023 (SCI-Expanded)
- XVI. **Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion**  
Horzum U., Yanik H., Taskiran E. Z., Esendagli G.  
IMMUNOLOGY, vol.167, no.4, pp.640-650, 2022 (SCI-Expanded)
- XVII. **Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes**  
KURŞUNEL M. A., Taskiran E. Z., Tavukcuoğlu E., Yanik H., Demirag F., KARAOSMANOĞLU B., Ozbay F. G., ÜNER A., Esendagli D., Kizilgoz D., et al.  
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol.71, no.2, pp.445-459, 2022 (SCI-Expanded)

- XVIII. **Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model**  
Unal S., ÖZTÜRK S. C., BİLGİÇ E., Yanik H., KORKUSUZ P., AKTAŞ Y., Benito J. M., ESENDAĞLI G., BİLENSOY E.  
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.169, pp.168-177, 2021 (SCI-Expanded)
- XIX. **Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier**  
Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., ÖZTÜRK S. C., ESENDAĞLI G., Khan M., ÇAPAN Y.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.66, 2021 (SCI-Expanded)
- XX. **Functional responsiveness of memory T cells from COVID-19 patients**  
Tavukcuoglu E., Horzum U., İNKAYA A. Ç., ÜNAL S., ESENDAĞLI G.  
CELLULAR IMMUNOLOGY, vol.365, 2021 (SCI-Expanded)
- XXI. **Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells**  
TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.63, 2021 (SCI-Expanded)
- XXII. **Proerythroblast Cells of Diamond-Blackfan Anemia Patients With RPS19 and CECR1 Mutations Have Similar Transcriptomic Signature**  
KARAOSMANOĞLU B., KURŞUNEL M. A., ÇETİNKAYA F. D., GÜMRÜK F., ESENDAĞLI G., ÜNAL Ş., Taskiran E. Z.  
FRONTIERS IN PHYSIOLOGY, vol.12, 2021 (SCI-Expanded)
- XXIII. **A robust optimization approach for the breast cancer targeted design of PEtOx-b-PLA polymersomes**  
ÖZ U. C., Bolat Z. B., Ozkose U. U., Gulyuz S., KÜÇÜKTÜRKMEN B., PARLAK KHALİLY M., ÖZÇUBUKÇU S., Yilmaz O., TELCİ D., ESENDAĞLI G., et al.  
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, vol.123, 2021 (SCI-Expanded)
- XXIV. **Clinical Relevance of Polymorphonuclear Myeloid-Derived Suppressor Cells in Autoimmune-Blistering Disorders Pemphigus Vulgaris and Bullous Pemphigoid**  
Oktem A., Horzum U., Ertop P., KUNDAKCI N., Akay B. N., Yalcin B., ESENDAĞLI G.  
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol.141, no.3, pp.672-676, 2021 (SCI-Expanded)
- XXV. **Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: Analyses in 3D tumor culture and tumor-bearing animals in vivo**  
Varan G., Varan C., Öztürk S. C., Benito J. M., Esendağlı G., Bilensoy E.  
Nanomaterials, vol.11, no.2, pp.1-18, 2021 (SCI-Expanded)
- XXVI. **CD66b(+) monocytes represent a proinflammatory myeloid subpopulation in cancer**  
Horzum U., Yoyen-Ermis D., Taskiran E. Z., Yilmaz K. B., HAMALOĞLU E., KARAKOÇ D., ESENDAĞLI G.  
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol.70, no.1, pp.75-87, 2021 (SCI-Expanded)
- XXVII. **Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer**  
Karpuz M., Silindir-Gunay M., Ozer A. Y., Ozturk S. C., Yanik H., Tuncel M., Aydin C., Esendagli G.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.156, 2021 (SCI-Expanded)
- XXVIII. **Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer**  
Tavukcuoglu E., Horzum U., Yanik H., ÜNER A., Yoyen-Ermis D., NURAL S. K., Aydin B., SÖKMENSÜER C., KARAKOÇ D., Yilmaz K. B., et al.  
EUROPEAN JOURNAL OF IMMUNOLOGY, vol.50, no.12, pp.2067-2074, 2020 (SCI-Expanded)
- XXIX. **An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy**  
Acar N. P., Tuncer A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., Sayat G., Taskiran E. Z., ESENDAĞLI G., KARABUDAK R.  
JOURNAL OF NEUROIMMUNOLOGY, vol.347, 2020 (SCI-Expanded)
- XXX. **Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer**

- KARPUZ M., Silindir-Gunay M., Kursunel M. A., ESENDAĞLI G., DOĞAN A., ÖZER A. Y.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.57, 2020 (SCI-Expanded)
- XXXI. **Development and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiforme**  
Sayiner O., Arisoy S., ÇOMOĞLU T., Ozbay F. G., ESENDAĞLI G.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.57, 2020 (SCI-Expanded)
- XXXII. **Transcriptional splice variants of CD40 and its prognostic value in breast cancer.**  
Ünver N., Yöyen E., Weber B., Esendağlı G.  
Turkish journal of biology = Turk biyoloji dergisi, vol.44, pp.73-81, 2020 (SCI-Expanded)
- XXXIII. **Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration**  
Caban-Toktas S., Sahin A., Lule S., Esendagli G., Vural İ., Karlı Oguz K., Soylemezoglu F., Mut M., Dalkara T., Khan M., et al.  
International Journal of Pharmaceutics, vol.578, 2020 (SCI-Expanded)
- XXXIV. **Aggregation of chitosan nanoparticles in cell culture: Reasons and resolutions**  
Ozturk K., Arslan F. B., Tavukcuoglu E., ESENDAĞLI G., ÇALIŞ S.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.578, 2020 (SCI-Expanded)
- XXXV. **Development and in vitro evaluation of a new adjuvant system containing Salmonella Typhi porins and chitosan**  
YÜKSEL S., PEKCAN M., PURALI N., ESENDAĞLI G., Tavukcuoglu E., Rivero-Arredondo V., Ontiveros-Padilla L., Lopez-Macias C., ŞENEL S.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.578, 2020 (SCI-Expanded)
- XXXVI. **PD-L2(+) wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses**  
Tavukcuoglu E., Horzum U., Yilmaz K. B., ESENDAĞLI G.  
IMMUNOLOGY AND CELL BIOLOGY, vol.98, no.2, pp.152-164, 2020 (SCI-Expanded)
- XXXVII. **Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation**  
Cassetta L., Bruderek K., Skrzeczynska-Moncznik J., Osiecka O., Hu X., Rundgren I. M., Lin A., Santegoets K., Horzum U., Godinho-Santos A., et al.  
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol.8, no.2, 2020 (SCI-Expanded)
- XXXVIII. **Protocol to assess the suppression of T-cell proliferation by human MDSC**  
Bruger A. M., Vanhaver C., Bruderek K., Amodio G., Tavukcuoglu E., ESENDAĞLI G., Gregori S., Brandau S., van der Bruggen P.  
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - CELLULAR METHODS, PT B, vol.632, pp.155-192, 2020 (SCI-Expanded)
- XXXIX. **A method for high-purity isolation of neutrophil granulocytes for functional cell migration assays**  
Avci E., Akkaya-Ulum Y. Z., Yoyen-Ermis D., ESENDAĞLI G., Balci-Peynircioglu B.  
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.44, no.6, pp.810-821, 2019 (SCI-Expanded)
- XL. **Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer**  
Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.54, 2019 (SCI-Expanded)
- XLI. **Identification of circulating MOG-specific B cells in patients with MOG antibodies**  
Winklmeier S., Schlueter M., Spadaro M., Thaler F. S., Vural A., Gerhards R., Macrini C., Mader S. A., Kurne A., İNAN B., et al.  
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, vol.6, no.6, 2019 (SCI-Expanded)
- XLII. **Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS**  
Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.  
SCIENTIFIC REPORTS, vol.9, 2019 (SCI-Expanded)

- XLIII. **Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival**  
Erol T, İmamoğlu N, Aydın B, Taşkıran Z. E., Esendağlı G., Kösemehmetoğlu K., Baykal A.  
MEDICINE, vol.98, no.33, 2019 (SCI-Expanded)
- XLIV. **Dual actions of the antioxidant chlorophyllin, a glutathione transferase P1-1 inhibitor, in tumorigenesis and tumor progression**  
ÖZCAN M., ESENDAĞLI G., Musdal Y., CANPINAR H., BACANLI M., Anlar H. G., Esendagli-Yilmaz G., Beyramzadeh M., AKSOY Y.  
JOURNAL OF CELLULAR BIOCHEMISTRY, vol.120, no.5, pp.7045-7055, 2019 (SCI-Expanded)
- XLV. **How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions**  
Bruger A. M., Dorhoi A., ESENDAĞLI G., Barczyk-Kahlert K., van der Bruggen P., Lipoldova M., Perecko T., Santibanez J., Saraiva M., Van Ginderachter J. A., et al.  
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol.68, no.4, pp.631-644, 2019 (SCI-Expanded)
- XLVI. **Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer**  
TİMUR S. S., Yoyen-Ermis D., Esendagli G., Yonat S., Horzum U., ESENDAĞLI G., GÜRİSOY R. N.  
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.136, pp.138-146, 2019 (SCI-Expanded)
- XLVII. **A Novel Missense LIG4 Mutation in a Patient With a Phenotype Mimicking Behcet's Disease**  
Taskiran E., Sonmez H., Kosukcu C., Tavukcuoglu E., Yazici G., Esendagli G., Batu E., Kiper P., Bilginer Y., Alikasifoglu M., et al.  
JOURNAL OF CLINICAL IMMUNOLOGY, vol.39, no.1, pp.99-105, 2019 (SCI-Expanded)
- XLVIII. **The fibrogenic activation kinetics of stromal stem cells in three different skeletal muscle degeneration models**  
Ozdemir C., Akcay D., Ermis D. Y., ESENDAĞLI G., Kocaefe C.  
FEBS OPEN BIO, vol.8, pp.93, 2018 (SCI-Expanded)
- XLIX. **Dual Effect of Glucocorticoid-Induced Tumor Necrosis Factor-Related Receptor Ligand Carrying Mesenchymal Stromal Cells on Small Cell Lung Cancer: A Preliminary in vitro Study**  
KÖPRÜ C. Z., Cagnan I., AKAR İ., ESENDAĞLI G., KORKUSUZ P., Gunel-Ozcan A.  
CYTOTHERAPY, vol.20, no.7, pp.930-940, 2018 (SCI-Expanded)
- L. **Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody**  
Yoyen-Ermis D., Ozturk-Atar K., KURŞUNEL M. A., Aydın C., Ozkazanc D., Gurbuz M. U., ÜNER A., TÜLÜ M., ÇALIŞ S., ESENDAĞLI G.  
MOLECULAR PHARMACEUTICS, vol.15, no.4, pp.1526-1533, 2018 (SCI-Expanded)
- LI. **Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics**  
ESENDAĞLI G., Yoyen-Ermis D., Guseinov E., Aras C., Aydın C., ÜNER A., HAMALOĞLU E., KARAKOÇ D.  
JOURNAL OF SURGICAL RESEARCH, vol.223, pp.188-197, 2018 (SCI-Expanded)
- LII. **Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer**  
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., Esendagli-Yilmaz G., Yoyen-Ermis D., Erdogdu B., SARGON M. F., EROĞLU H., BİLENSOY E.  
JOURNAL OF DRUG TARGETING, vol.26, no.1, pp.66-74, 2018 (SCI-Expanded)
- LIII. **Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection**  
Kara A., Ozturk N., ESENDAĞLI G., Ozkose U. U., Gulyuz S., Yilmaz O., Telci D., Bozkir A., VURAL İ.  
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, vol.46, 2018 (SCI-Expanded)
- LIV. **Effect of Usnic Acid/Paclitaxel Co-Administration on Mouse (4T1) Breast Cancer Cell Lines**  
DİNÇSOY A. B., Ermis D. Y., CANSARAN DUMAN D., TUNCER M., KARABULUT İ., ESENDAĞLI G.  
ACTA PHYSIOLOGICA, vol.221, pp.40-41, 2017 (SCI-Expanded)
- LV. **A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy**

- KURŞUNEL M. A., ESENDAĞLI G.  
EBIOMEDICINE, vol.23, pp.6-7, 2017 (SCI-Expanded)
- LVI. **Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers**  
Ozturk K., ESENDAĞLI G., Gurbuz M. U., TÜLÜ M., ÇALIŞ S.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.517, pp.157-167, 2017 (SCI-Expanded)
- LVII. **Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells**  
Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., ESENDAĞLI G., ÇAPAN Y.  
JOURNAL OF MICROENCAPSULATION, vol.34, no.7, pp.659-666, 2017 (SCI-Expanded)
- LVIII. **Th1 cells in cancer-associated inflammation**  
Dinc Akbulut G., Ozkazanc D., ESENDAĞLI G.  
TURKISH JOURNAL OF BIOLOGY, vol.41, no.1, pp.20-30, 2017 (SCI-Expanded)
- LIX. **Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis**  
Sevmis M., Yoyen-Ermis D., Aydin C., BİLGİÇ E., KORKUSUZ P., ÜNER A., HAMALOĞLU E., ESENDAĞLI G., KARAKOÇ D.  
IMMUNOLOGICAL INVESTIGATIONS, vol.46, no.7, pp.663-676, 2017 (SCI-Expanded)
- LX. **A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery**  
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.  
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, vol.45, no.8, pp.1657-1664, 2017 (SCI-Expanded)
- LXI. **Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells**  
Özkazanc D., Yöyen-Ermis D., Tavukçuoğlu E., BÜYÜKAŞIK Y., ESENDAĞLI G.  
IMMUNOLOGY, vol.149, no.4, pp.460-471, 2016 (SCI-Expanded)
- LXII. **The untold story of IFN-gamma in cancer biology**  
KURŞUNEL M. A., ESENDAĞLI G.  
CYTOKINE & GROWTH FACTOR REVIEWS, vol.31, pp.73-81, 2016 (SCI-Expanded)
- LXIII. **Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles**  
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., ŞEN M., ÖNER L., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.509, pp.375-390, 2016 (SCI-Expanded)
- LXIV. **Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers**  
Gurbuz M. U., Ozturk K., Erturk A. S., YOYEN-ERMIS D., ESENDAĞLI G., ÇALIŞ S., TÜLÜ M.  
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, vol.27, no.16, pp.1645-1658, 2016 (SCI-Expanded)
- LXV. **CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC tumors.**  
Unver N., ESENDAĞLI G., YILMAZ G., GUC D.  
Cytokine, vol.75, pp.330-7, 2015 (SCI-Expanded)
- LXVI. **Immune system in cancer and hydatid disease: cross-reactivity vs. immune modulation**  
ESENDAĞLI G., ABBASOĞLU O.  
PARASITE IMMUNOLOGY, vol.37, no.8, pp.427-428, 2015 (SCI-Expanded)
- LXVII. **Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma**  
DOLEN Y., GÜNAYDIN G., ESENDAĞLI G., GUC D.  
CELLULAR IMMUNOLOGY, vol.295, no.1, pp.29-35, 2015 (SCI-Expanded)
- LXVIII. **CRAM-A indicates IFN-gamma-associated inflammatory response in breast cancer**  
SARMADI P., Tunali G., Esendagli-Yilmaz G., YILMAZ K. B., ESENDAĞLI G.  
MOLECULAR IMMUNOLOGY, vol.68, no.2, pp.692-698, 2015 (SCI-Expanded)
- LXIX. **Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide**

- KILIÇ A., ESENDAĞLI G., SAYAT G., TALİM B., KARABUDAK R., KURNE A.  
AUTOIMMUNITY, vol.48, no.6, pp.423-428, 2015 (SCI-Expanded)
- LXX. **Co-existence of Echinococcus granulosus infection and cancer metastasis in the liver correlates with reduced Th1 immune responses**  
Turhan N., ESENDAĞLI G., Ozkayar O., Tunali G., SÖKMENSÜER C., ABBASOĞLU O.  
PARASITE IMMUNOLOGY, vol.37, no.1, pp.16-22, 2015 (SCI-Expanded)
- LXXI. **T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands**  
Karasar P., ESENDAĞLI G.  
BREAST CANCER RESEARCH AND TREATMENT, vol.145, no.3, pp.605-614, 2014 (SCI-Expanded)
- LXXII. **Spheroid formation and invasion capacity are differentially influenced by co-cultures of fibroblast and macrophage cells in breast cancer**  
Rama-Esendagli D., ESENDAĞLI G., Yilmaz G., Guc D.  
MOLECULAR BIOLOGY REPORTS, vol.41, no.5, pp.2885-2892, 2014 (SCI-Expanded)
- LXXIII. **Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line**  
Sengel-Turk C. T., Hascicek C., DOĞAN A., ESENDAĞLI G., Guc D., Gonul N.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.24, no.2, pp.166-172, 2014 (SCI-Expanded)
- LXXIV. **A co-stimulatory trap set by myeloid leukemia cells**  
Esendagli G.  
ONCOIMMUNOLOGY, vol.2, no.6, 2013 (SCI-Expanded)
- LXXV. **Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands**  
Dolen Y., ESENDAĞLI G.  
EUROPEAN JOURNAL OF IMMUNOLOGY, vol.43, no.3, pp.747-757, 2013 (SCI-Expanded)
- LXXVI. **Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy**  
ESENDAĞLI G., Kurne A. T., Sayat G., Kilic A. K., Guc D., KARABUDAK R.  
JOURNAL OF NEUROIMMUNOLOGY, vol.255, pp.81-84, 2013 (SCI-Expanded)
- LXXVII. **The effect of granulocyte colony stimulating factor receptor gene missense single nucleotide polymorphisms on peripheral blood stem cell enrichment**  
CAMURDANOGLU B. Z., ESENDAĞLI G., Ozdemir E., CANPINAR H., Guc D., Kansu E.  
CYTOKINE, vol.61, no.2, pp.572-577, 2013 (SCI-Expanded)
- LXXVIII. **Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells**  
Sengel-Turk C. T., Hascicek C., DOĞAN A., ESENDAĞLI G., Guc D., Gonul N.  
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.38, no.9, pp.1107-1116, 2012 (SCI-Expanded)
- LXXIX. **Injectable biodegradable polymeric system for preserving the active form and delayed-release of camptothecin anticancer drugs**  
Mert O., ESENDAĞLI G., DOĞAN A., DEMİR A. G.  
RSC ADVANCES, vol.2, no.1, pp.176-185, 2012 (SCI-Expanded)
- LXXX. **Expression of chemokine-like receptor 1 (CMKLR1) on J744A.1 macrophages co-cultured with fibroblast and/or tumor cells: Modeling the influence of microenvironment**  
Rama D., ESENDAĞLI G., Guc D.  
CELLULAR IMMUNOLOGY, vol.271, no.1, pp.134-140, 2011 (SCI-Expanded)
- LXXXI. **Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy**  
Kurne A., Guc D., CANPINAR H., Aydin O. F., Sayat G., Yorubulut M., ESENDAĞLI G., KARABUDAK R.  
ACTA NEUROLOGICA SCANDINAVICA, vol.123, no.1, pp.8-12, 2011 (SCI-Expanded)
- LXXXII. **Immune Compartmentalization of T cell Subsets in Chemically-induced Breast Cancer**  
Fahmi T., ESENDAĞLI G., Yilmaz G., Kansu E., Guc D.



- SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol.72, no.4, pp.339-348, 2010 (SCI-Expanded)
- LXXXIII. **CD40-1C > T single nucleotide polymorphism and CD40 expression on breast tumors**  
Dolen Y, Yilmaz G., ESENDAĞLI G., Guler N. E., Guc D.  
CYTOKINE, vol.50, no.3, pp.243-244, 2010 (SCI-Expanded)
- LXXXIV. **Transfection of myeloid leukaemia cell lines is distinctively regulated by fibronectin substratum**  
ESENDAĞLI G., CANPINAR H., DOĞAN A., Akkaya M., Kansu E., Guc D.  
CYTOTECHNOLOGY, vol.61, pp.45-53, 2009 (SCI-Expanded)
- LXXXV. **Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors**  
Bilensoy E., Sarisozen C., Esendagli G., Doğan A., Aktas Y., Şen M., Mungan N. A.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.371, pp.170-176, 2009 (SCI-Expanded)
- LXXXVI. **CONSTRUCTION OF BICISTRONIC B-GALACTOSIDASE REPORTER PLASMIDS FOR EUKARYOTIC EXPRESSION OF CD40 LIGAND (CD40L) GENE**  
Dolen Y., ESENDAĞLI G., Oskay S., Guc D.  
IUBMB LIFE, vol.61, no.3, pp.335, 2009 (SCI-Expanded)
- LXXXVII. **Fibronectin promotes the phorbol 12-myristate 13-acetate-induced macrophage differentiation in myeloid leukemia cells**  
ESENDAĞLI G., CANPINAR H., Yilmaz G., KAYMAZ F. F., Kansu E., Guc D.  
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.89, no.2, pp.167-172, 2009 (SCI-Expanded)
- LXXXVIII. **Molecular and functional analysis of a novel recombinant clone of rat (*Rattus norvegicus*) CD40 ligand (CD40L) gene**  
ESENDAĞLI G., Gunel-Ozcan A., CANPINAR H., Guc D.  
MOLECULAR BIOLOGY REPORTS, vol.36, no.1, pp.83-89, 2009 (SCI-Expanded)
- LXXXIX. **Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene**  
ESENDAĞLI G., CANPINAR H., Yilmaz G., Gunel-Ozcan A., Guc M. O., Kansu E., Guc D.  
CANCER BIOLOGY & THERAPY, vol.8, no.2, pp.136-142, 2009 (SCI-Expanded)
- XC. **Coexistence of different tissue tumorigenesis in an N-methyl-N-nitrosourea-induced mammary carcinoma model: a histopathological report in Sprague-Dawley rats**  
ESENDAĞLI G., Yilmaz G., CANPINAR H., Gunel-Ozcan A., Guc M. O., Guc D.  
LABORATORY ANIMALS, vol.43, no.1, pp.60-64, 2009 (SCI-Expanded)
- XCII. **Adhesion of beta1 integrin to fibronectin regulates CAM-DR phenotype via p21(WAF1/cip1) in HL60 acute myeloid leukemia (AML) cells**  
CANPINAR H., ESENDAĞLI G., Kansu E., Ozcan A. G., Guc D.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.38, no.2, pp.97-104, 2008 (SCI-Expanded)
- XCIII. **Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer**  
Esendagli G., Bruderek K., Goldmann T., Busche A., Branscheid D., Vollmer E., Brandau S.  
LUNG CANCER, vol.59, no.1, pp.32-40, 2008 (SCI-Expanded)
- XCIII. **Salmonella typhimurium aroB encoding murine IL 18 or CD40L evaluation for gene therapy**  
AYDIN D., GÜNEL ÖZCAN A., MENAGER N., ESENDAĞLI G., GÜÇ M. O., HAYRAN K. M., Kansu E., GÜÇ D.  
Febs Journal, vol.273, pp.49-50, 2006 (SCI-Expanded)
- XCIV. **pTARGET vector carrying IL 18 or CD40L genes for attenuated Salmonella typhimurium mediated gene therapy**  
BEK D., ESENDAĞLI G., GÜNEL ÖZCAN A., GÜÇ D., GÜÇ M. O., Kansu E.  
Blood, vol.102, pp.491, 2003 (SCI-Expanded)

## Articles Published in Other Journals

1. **Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination.**

Hafızoğlu M., Bas A. O., Tavukçuoğlu E., Sahiner Z., Oytun M. G., Ulutürk S., Yanık H., Doğu B. B., Cankurtaran M., Esendağlı G., et al.

Clinical immunology communications, vol.2, pp.154-158, 2022 (Peer-Reviewed Journal)

II. **Design and synthesis of novel peptidomimetics for cancer immunotherapy**

Kose C., Uysal E., Yazici B., Tugay Z., Dingis-Birgul S. I., Yanık H., Tavukcuoglu E., Gulyuz S., AKDEMİR A., ESENDAĞLI G., et al.

ORGANIC COMMUNICATIONS, vol.13, no.3, pp.89-102, 2020 (ESCI)

III. **Tümörlerde Doğal İmmün Yanıt**

ÖZMEN F., ESENDAĞLI G.

Turkiye Klinikleri J Med Oncol-Special Topics, vol.10, pp.104-111, 2017 (Peer-Reviewed Journal)

IV. **Atypical Chemokine Receptors in Cancer**

sarmadi p., TUNALI G., ESENDAĞLI G.

Acta Medica, 2016 (Peer-Reviewed Journal)

## Books & Book Chapters

I. **Biomaterials Surface Properties: Implications in Immune Response**

ENDOĞAN TANIR T., ESENDAĞLI G., AKSOY E. A.

in: Biomaterials and Immune Response: Complications, Mechanisms and Immunomodulation, Vrana, Nihal Engin, Editor, CRC Press Taylor Francis Group, pp.121-140, 2018

## Refereed Congress / Symposium Publications in Proceedings

I. **NUSİNERSEN TEDAVİSİ ALAN ERİŞKİN SPİNAL MUSKÜLER ATROFİ HASTALARINDA İNFLAMASYON VE GLİAL HÜCRE İLİŞKİLİ BİYOBELİRTEÇLERİN TESPİTİ**

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., KURT C. E.

59. Ulusal Nöroloji Kongresi, Antalya, Turkey, 13 December 2023

II. **MİYASTENİK KRİZ İLE BAŞVURAN HASTALARDA YARDIMCI FOLİKÜLER T HÜCRE (TFH) VE YARDIMCI T HÜCRE 17 (TH17) İLİŞKİLİ SİTOKİNLERİN TEDAVİ ÖNCESİ VE SONRASI DEĞİŞKENLİĞİ**

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., KURT C. E.

59. Ulusal Nöroloji Kongresi, Antalya, Turkey, 13 December 2023

III. **Evaluation of the Role of Glial Factors in the Pathogenesis of Spinal Muscular Atrophy**

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., İNAN B., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., KURT C. E.

2023 Neuromuscular Study Group Meeting, Orlando, United States Of America, 22 September 2023

IV. **Serum Cytokines Levels in Patients with Myasthenia Gravis and Their Changes After Treatment**

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., KURT C. E.

75th Annual Meeting of the American-Academy-of-Neurology (AAN), Boston, United States Of America, 22 April 2023

V. **Büyük veriden hücre karakterizasyonuna: Transkripsiyon faktörü kataloglarının oluşturulması**

İMREN G., KARAOSMANOĞLU B., ÇELEBİ SALTİK B., ESENDAĞLI G., TAŞKIRAN Z. E.

Tıbbi Biyoloji ve Genetik Kongresi, Turkey, 27 - 30 October 2019

VI. **Effect of Formulation Parameters on PLGA and PLGA-PEG Nanoparticles Formulated with Double Emulsion Method**

Arslan F. B., ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.

8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 October 2019

VII. **A Modified Cell Culture Method for Evaluation of Chitosan Nanoparticles**

ÖZTÜRK K., Arslan F. B., Tavukçuoğlu E., ESENDAĞLI G., ÇALIŞ S.

8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 October 2019

VIII. **Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of**

## **Doxorubicin In Breast Cancer**

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.

8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019, vol.1, pp.184-186

- IX. **A positive feedback mechanism between basal-like breast cancer cells and monocytes through STAT3/IL-1 beta/fibronectin can support chronic inflammation in the tumor microenvironment**  
Tunali G., ESENDAĞLI G.  
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, China, 19 - 23 October 2019, vol.49, pp.486
- X. **STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells**  
Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.  
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, China, 19 - 23 October 2019, vol.49, pp.90
- XI. **Transcriptomic and immunophenotypic analyses on natural killer cells in RRMS patients under fingolimod therapy**  
Acar-Ozen N. P., TUNCER A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., Taskiran E., ESENDAĞLI G., KARABUDAK R.  
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.664-665
- XII. **Circulating myelin oligodendrocyte glycoprotein (MOG)-specific B cells stratify patients with serum MOG-antibodies**  
Winkmeier S., Schlueter M., Spadaro M., Thaler F. S., Vural A., Gerhards R., Macrini C., Mader S., Kurne A., İNAN B., et al.  
2nd Joint Meeting of the German-Society-for-Immunology (DGfI) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA), Munich, Germany, 10 - 13 September 2019, vol.49, pp.77
- XIII. **Small cell lung cancer stem cells show adaptive resistance through effectively inducing t cell activation and modulating the expression of co-inhibitory receptor**  
KURŞUNEL M. A., TAŞKIRAN Z. E., ESENDAĞLI G.  
International Molecular Immunology Immunogenetics Congress IV (MIMIC IV), Bursa, Turkey, 27 - 29 April 2019, pp.29
- XIV. **Analysis of spleen-derived MDSCs in pancreatic and gastric cancer patients**  
tavukcuoglu e., horzum u., Yoyen-Ermis D., aydin b., Yılmaz B. K., ÜNER A., KARAKOÇ D., Hamaloglu E., ESENDAĞLI G.  
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018
- XV. **Transcript variants of MDSC-related surface markers in breast cancer and colorectal cancer**  
horzum u., Yoyen-Ermis D., Yılmaz B. K., KARAKOÇ D., ESENDAĞLI G.  
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018
- XVI. **Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis**  
Yoyen-Ermis D., Sevmis M., Aydin C., Bilgic E., KORKUSUZ P., ÜNER A., Hamaloglu E., KARAKOÇ D., ESENDAĞLI G.  
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018
- XVII. **APOPTOTIC GENE THERAPY BY NOVEL DEVELOPED PARTIALLY HYDROLYSED PEtOx BASED MICELLAR NANOCARRIERS ON MCF-7 BREAST CANCER CELLS**  
KARA A., ÖZTÜRK N., ESENDAĞLI G., ÖZKÖSE U. U., Gulyuz S., bolat z. b., Yılmaz O., TELCİ D., BOZKIR A., VURAL İ.  
IPTS2018, 17 - 19 September 2018
- XVIII. **In Vitro Evaluation of Co-Loaded Drug Delivery, Theranostic Liposomes in Human Non-Small Cell Lung Cancer**  
KARPUZ M., KURŞUNEL M. A., SİLİNDİR GÜNAY M., DOĞAN A., ESENDAĞLI G., ÖZER A. Y.  
19th International Pharmaceutical Technology Symposium, Antalya, Turkey, 17 September 2018, pp.182-183
- XIX. **PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES**

- TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.  
19th International Pharmaceutical Technology Symposium-IPTS 2018, 17 - 19 September 2018
- XX. **Characterization of Circulating Exosomes and Analysis of Exosomal microRNAs**  
zeynep t., AKKAYA ULUM Z. Y., YERSAL N., AKBABA T. H., Horzum U., ESENDAĞLI G., KORKUSUZ P., peynircioglu b.  
6th International Congress of the Molecular Biology of Association of Turkey, 5 - 08 September 2018
- XXI. **Preparation and Comparative Evaluation of Gemcitabine Loaded Polymeric Nanoparticles for Pancreatic Cancer Treatment**  
Arslan F. B., ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.  
45th Annual Meeting Exposition of the Controlled Release Society, 22 - 24 July 2018
- XXII. **The Fibrogenic Activation Kinetics of Stromal Stem Cells in Three Different Skeletal Muscle Degeneration Models**  
ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., ESENDAĞLI G., KOCAEFE Y. Ç.  
43rd FEBS CONGRESS, 7 - 12 July 2018
- XXIII. **Comparative Transcriptome Analysis of Distinct Stromal Cell Populations During Extracellular Matrix Remodeling in Skeletal Muscle**  
ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., TAŞKIRAN Z. E., ESENDAĞLI G., KOCAEFE Y. Ç.  
13th Meeting of the Mediterranean Society of Myology, 27 - 29 June 2018, vol.37, pp.129-183
- XXIV. **Leptinin Spermatogonyal Kok Hücreler Uzerindeki Etkisi**  
YERSAL N., KÖSE S., Utku H., ESENDAĞLI G., Sinan O., KORKUSUZ P.  
XIV. Ulusal Histoloji ve Embriyoloji Kongresi, Turkey, 10 May 2019 - 13 May 2018
- XXV. **Gemcitabine delivery via dendrimer carriers decorated with anti-VGFR1 antibody to target tumor-induced myeloid cells**  
KURŞUNEL M. A., Yoyen Ermis D., OZTURK ATAR K., AYDIN Ç., OZKAZANC D., GURBUZ M. U., ÜNER A., TULU M., ÇALIŞ S., ESENDAĞLI G.  
Myeloid Derived Suppressor Cells: Identification and implications in Human Diseases, 16 - 18 April 2018
- XXVI. **Passive Targeting of Gemcitabine Using Poly(Caprolactone) Nanoparticles for Cancer Treatment**  
ÖZTÜRK K., Arslan F. B., ESENDAĞLI G., ÇALIŞ S.  
2nd Gazi Pharma Symposium Series, 11 - 13 October 2017
- XXVII. **Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers**  
ÖZTÜRK K., ESENDAĞLI G., Gürbüz M. U., TULÜ M., ÇALIŞ S.  
Advanced School in Nanomedicine, 25 - 28 September 2017
- XXVIII. **Dual effects of chlorophylline on breast cancer cell proliferation in vivo and in vitro**  
ÖZCAN M., Musad Y., ESENDAĞLI G., CANPINAR H., AKSOY Y.  
42nd Congress of the Federation-of-European-Biochemical-Societies (FEBS) on From Molecules to Cells and Back, Jerusalem, Israel, 10 - 14 September 2017, vol.284, pp.259
- XXIX. **Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer**  
ERDOĞAR N., ESENDAĞLI G., NIELSEN T. T., ESENDAĞLI YILMAZ G., SARGON M. F., ÖNER L., BİLENSOY E.  
Innovation in Medicine Summit-3, 11 - 13 May 2017
- XXX. **NOVEL POLYMERIC MICELLES BASED ON Poly-(2-Ethyl-2-Oxazoline)-co-Poly(ethylenimine)-block-Poly(ε-caprolactone) PETox-co-PEI-b-PCL BLOCK COPOLYMER WITH VARIOUS HYDROLYSIS DEGREE TO EVALUATE THE EFFECT OF TRANSFECTION EFFICIENCY ON MCF-7 CELLS**  
KARA A., ÖZTÜRK N., ESENDAĞLI G., BOLAT z. b., GÜLYÜZ s., TELCİ D., YILMAZ ö., BOZKIR A., VURAL İ.  
AAPS 2017 NATIONAL BIOTECHNOLOGY CONGRESS, San Diego, United States Of America, 01 May 2107 - 03 May 2017
- XXXI. **Increased monocytic myeloid-derived suppressor cells in small-cell lung cancer implicate interaction between small cell lung cancer cells and monocytes**  
KURŞUNEL M. A., Yoyen Ermis D., Horzum U., Esendagli D., ESENDAĞLI G.  
Analysis and Clinical Monitoring of Myeloid Regulatory Cells, Brno, Czech Republic, 1 - 03 March 2017
- XXXII. **Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges**

ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.

GPEN 2016, 9 - 12 November 2016

- XXXIII. **Intracellular delivery and intraperitoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method**  
ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.  
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 September 2016
- XXXIV. **Effect of chlorophylline as an antioxidant molecule on glutathione and related enzymes in breast cancer model**  
ÖZCAN M., Beyramzadeh M., ESENDAĞLI G., AKSOY Y.  
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.408
- XXXV. **The effect of fingolimod treatment on natural killer cells**  
Acar N. P., KARABUDAK R., Ozkazanc D., Sayat-Gurel G., ESENDAĞLI G., TUNCER A.  
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.176-177
- XXXVI. **Active targeting of anti VEGFR 1 monoclonal antibody conjugated gemcitabine loaded dendrimers to pancreatic cancer and in vitro in vivo evaluation**  
ÖZTÜRK K., gurbuz u. m., TÜLÜ M., ESENDAĞLI G., ÇALIŞ S.  
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXXVII. **Costimulatory signals derived from myeloid leukemia cells contribute to functional exhaustion in CD4(+) T cells**  
Ozkazanc D., BÜYÜKAŞIK Y., ESENDAĞLI G.  
International Congress of Immunology (ICI), Melbourne, Australia, 21 - 26 August 2016, vol.46, pp.1092-1093
- XXXVIII. **Targeting myeloid derived suppressor cells MDSCs in pancreatic cancer by gemcitabine loaded anti VEGFR1 antibody coated dendrimers carriers**  
ÖZTÜRK K., yöyen ermiş d., özkazanç d., gürbüz m. u., TÜLÜ M., ÇALIŞ S., ESENDAĞLI G.  
3rd International Molecular Immunology & Immunogenetics Congress MIMIC-III, 27 - 30 April 2016
- XXXIX. **B7-H3 molekülünün küçük-hücreli akciğer kanseri için immünolojik biyobelirteç olarak değerlendirilmesi**  
KURŞUNEL M. A., ESENDAĞLI D., ESENDAĞLI G.  
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017
- XL. **THE PROTECTIVE ROLE OF CHLOROPHYLLINE Cu COMPLEX ON N METHYL N NITROSOUREA INDUCED BREAST CANCER MODEL**  
ÖZCAN M., BÜBER E., CEYHAN D., beyramzadeh m., BACANLI M., ESENDAĞLI G., AKSOY Y.  
XXVII. ULUSAL BİYOKİMYA KONGRESİ, 3 - 06 November 2015, vol.40
- XLI. **Evaluation of Developed Dendrimer based Nanocarrier System for Pancreatic Cancer Therapy**  
ÖZTÜRK K., Gürbüz M., Tülü M., ESENDAĞLI G., ÇALIŞ S.  
2015 AAPS Annual Meeting and Exposition, 25 October - 29 June 2015
- XLII. **Evaluation of Dendrimer Based Nanocarrier System for Pancreatic Cancer Therapy**  
ÖZTÜRK K., Gürbüz M. U., ESENDAĞLI G., TÜLÜ M., ÇALIŞ S.  
2015 AAPS Annual Meeting, 25 - 29 October 2015
- XLIII. **Immune modulatory effects of the small peptide molecules derived from CXCL chemokines**  
Yöyen Ermis D., Karaşar P., ESENDAĞLI G.  
World Immunoregulation meeting – IX, 18 - 21 March 2015
- XLIV. **In Vitro and In Vivo Evaluation of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin Derivatives**  
ERDOĞAR N., TERNDRUP N., ÖNER L., ESENDAĞLI G., BİLENSOY E.  
4th European Conference on Cyclodextrins (EUROCD 2015), 6 - 09 October 2015
- XLV. **Mesenchymal stem cells induce proliferation of NCI-H82 small cell lung cancer**  
KOPRU C. Z., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., KORKUSUZ P., ÖZCAN A.  
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-

Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26

- XLVI. **pCR3::GITRL transfected MSCs induce apoptotic cell death and SIVA1 expression in SCLC-21H lung cancer cell line**  
KOPRU C. Z., KORKUSUZ P., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., ÖZCAN A.  
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26
- XLVII. **Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma**  
DÖLEN Y., GÜNAYDIN G., ESENDAĞLI G., GÜÇ D.  
4TH EUROPEAN CONGRESS OF IMMUNOLOGY, 6 - 09 September 2015
- XLVIII. **The effect of co stimulatory signals derived from acute myeloid leukemia cells AML on helper T lymphocyte activation and exhaustion**  
OZKAZANC D., ESENDAĞLI G.  
4th European Congress of Immunology, 6 - 09 September 2015
- XLIX. **Fibronectin production in basal like breast cancer cells is regulated by pro inflammatory cytokines and may influence myeloid cell maturation**  
TUNALI G., ESENDAĞLI G.  
4th European Congress of Immunology, 6 - 09 September 2015
- L. **Selective expression of CCRL2 transcript variants associates with inflammatory response in breast cancer**  
Sarmadi P., TUNALI G., YILMAZ G., Yılmaz K., ESENDAĞLI G.  
4th European Congress of Immunology, 6 - 09 September 2015
- LI. **Nanopartiküller ile işaretli pGITRL aktarılmış mezenkimal kök hücrelerin küçük hücreli akciğer kanseri hücreleriyle görüntülenmesi**  
KÖPRÜ C. Z., GÜNEL ÖZCAN A., Cagnan I., AKAR SOYCAN İ., ESENDAĞLI G., KORKUSUZ P.  
22.nci Elektron Mikroskopi Kongresi (EMK 2015), İstanbul, Turkey, 2 - 04 September 2015
- LII. **Can acute myeloid leukemia cells act as myeloid derived suppressor cells for immune escape**  
YÖYEN ERMİŞ D., TUNALI G., KARAŞAR P., ESENDAĞLI G.  
Young Investigator Workshop Immunology and Microenvironments Implications for Cancer Therapy, 24 - 26 August 2015
- LIII. **The protective role of chlorophylline-Cu complex on N-methyl-N-nitrosourea induced breast cancer model in Sprague Dawley Rats: glutathione and DNA damage levels**  
ÖZCAN M., BÜBER E., Ceyhan D., BACANLI M., Beyramzadeh M., ESENDAĞLI G., AKSOY Y.  
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Germany, 4 - 09 July 2015, vol.282, pp.265
- LIV. **Optimization by 32 Factorial Design of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin**  
ERDOĞAR N., ÖNER L., ESENDAĞLI G., NIELSEN T., BİLENSOY E.  
EUFEPS Annual Meeting, 15 - 17 June 2015
- LV. **Evaluation of Th17 cell infiltration in thymectomy materials of acetylcholine receptor antibody positive myasthenia gravis patients**  
Bekircan Kurt E., Mehdikanova L., Öner S., ESENDAĞLI G., KARABULUT E., Kurne A.  
AAN 67th Annual Meeting, 6 - 10 April 2015
- LVI. **Formyl-methionyl-leucyl-phenylalanine (fMLP) peptide as an adjuvant in experimental autoimmune encephalomyelitis (EAE): modulation of neutrophil granulocytes**  
KILIÇ A., Tuncer-Kurue A., ESENDAĞLI G., Sayat G., TALİM B., KARABUDAK R.  
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.136
- LVII. **NMU ARACILI MEME KANSERİ MODELİNDE MYELOİD KÖKENLİ BASKILAYICI HÜCRELERİN TANIMLANMASI**  
DÖLEN Y., GÜNAYDIN G., ESENDAĞLI G., GÜÇ D.  
22. ULUSAL İMMÜNOLOJİ KONGRESİ, Turkey, 27 - 30 April 2013

- LVIII. Evaluation of Th17-related parameters in multiple sclerosis patients under immunomodulatory IFN-beta 1 therapy**  
Sayat G., Kurne A., ESENDAĞLI G., Guc D., KARABUDAK R.  
11th International Congress of Neuroimmunology (ISNI), Massachusetts, United States Of America, 4 - 08 November 2012, vol.253, pp.77-78
- LIX. Cloning of atypical chemokine receptors CRAM-A and CRAM-B for comparative functional analysis**  
Sarmadi P., ESENDAĞLI G.  
European Congress of Immunology, Glasgow, United Kingdom, 5 - 08 September 2012, vol.137, pp.188
- LX. Differences of myeloid cell subsets in a chemically induced rat breast carcinoma model**  
DOLEN Y., GÜNEYDİN G., ESENDAĞLI G., Guc D.  
European Congress of Immunology, Glasgow, United Kingdom, 5 - 08 September 2012, vol.137, pp.606
- LXI. Functional analysis of neutrophils cultured in supernatant of CXCL7 overexpressing lung cancer cells**  
ÜNVER N., ESENDAĞLI G., Guc D.  
European Congress of Immunology, Glasgow, United Kingdom, 5 - 08 September 2012, vol.137, pp.608
- LXII. Dynamic induction of immune escape by activated T cells via regulation of B7-ligands on myeloid leukemia cells**  
ESENDAĞLI G., Dolen Y.  
European Congress of Immunology, Glasgow, United Kingdom, 5 - 08 September 2012, vol.137, pp.206-207
- LXIII. Salmonella typhimurium aroB-encoding murine IL-18 or CD40L: evaluation for gene therapy**  
Aydın D., Gunel-Ozcan A., Menager N., Esendagli G., Guc M. O., Hayran M., Kansu E., Guc D.  
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.49-50
- LXIV. pTARGET vector carrying IL-18 or CD40L genes for attenuated Salmonella typhimurium mediated gene therapy.**  
Bek D., Esendagli G., Gunel-Ozcan A., Guc D., Guc M., Kansu E.  
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

## Supported Projects

ESENDAĞLI G., TUBITAK Project, Prostat ve meme kanseri teşhis ve tedavisinde kullanılacak Poli 2 Etil 2 Oksazolin Petox esaslı çok işlevsel taşıyıcı sistemlerin geliştirilmesi, 2014 - Continues

Aydın S., Ünal S., Tatar Yılmaz G., Özçubukçu S., Özkul A., Esendağlı G., Varan G., Research Project of the Presidency of Turkey Health Institutes (TÜSEB), Covid 19'a Karşı Multi-epitop (Wuhan, Delta, Omicron B.A/5 ) Sentetik Peptid Aşısı Araştırma Geliştirme Çalışması, 2023 - 2025

ESENDAĞLI G., ÖZTÜRK S. C., Gökşen S., Project Supported by Higher Education Institutions, Folat reseptörü ifade eden immün hücrelerin tümör mikroçevresine infiltrasyonu ve immünoterapi amacıyla modülasyonu, 2021 - 2022

ESENDAĞLI G., Ulusoy S., Project Supported by Higher Education Institutions, Mikrotübül İnhibitörlerinin Kanser Hücrelerinde Tehlike-ilişkili Moleküler Desen Düzeylerine Etkisinin Araştırılması, 2020 - 2021

ERCAN A., ÖZTÜRK S. C., AYTEMİR M., ESENDAĞLI G., Project Supported by Higher Education Institutions, Klorokojik Asit Türevi Mannich Bazı Bileşiminin UV ile İndüklenmiş Melanoma Karşı Koruyucu Etkisinin Değerlendirilmesi, 2019 - 2021

ESENDAĞLI G., TAŞKIRAN Z. E., Horzum U., Project Supported by Higher Education Institutions, Farklı aktivasyon basamaklarına ilerletilen yardımcı T hücrelerinde adezyon ve migrasyon mekanizmalarının incelenmesi, 2018 - 2021

BİLENSOY E., Varan G., ESENDAĞLI G., Varan C., Project Supported by Higher Education Institutions, Paklitaksel yüklü siklodekstrin nanopartiküllerin antitümöral etkinliğinin araştırılması, 2017 - 2020

ESENDAĞLI G., ÖZBAY F., Project Supported by Higher Education Institutions, T lenfosit yanıtlarının nötrofil, monosit ve akciğer kanseri hücrelerini içeren kokültürlerde analizi, 2018 - 2019

ESENDAĞLI G., TUNALI G., Project Supported by Higher Education Institutions, Meme kanseri hücreleri tarafından üretilen fibronektinin miyeloid hücre karakteri üzerine etkisi, 2018 - 2019



KARAKOÇ D., YORGUN H., ÜNAL CANGÜL Ş., ER ÖZTAŞ Y., ESENDAĞLI G., KONAŞ E., ÇALIK BAŞARAN N., KILIÇASLAN B., EKİNCİ S., HELVACI E., et al., Project Supported by Higher Education Institutions, Hacettepe Üniversitesi Tıp Fakültesi Dergisi Acta Medica'nın Yapılandırılması, 2017 - 2019

ÖZER A. Y., SİLİNDİR GÜNAY M., ESENDAĞLI G., KARPUZ M., Project Supported by Higher Education Institutions, Küçük Hücreli Dışı Akciğer Kanserine Aktif Hedeflendirilmiş Nanoboyutlu Teranostik Kombine İlaç Taşıyan Sistemlerin Formülasyonu ve Etkinliğinin Saptanması, 2017 - 2019

TUNCER M. A., ACAR N. P., ESENDAĞLI G., SAYAT-GÜREL G., KARABUDAK R., Project Supported by Higher Education Institutions, Multiple Skleroz Hastalarında CCRL2 Atipik Kemokin Reseptör Polimorfizminin Kemokin Düzeyleri ve Hastalık Süreci ile İlişkisi, 2015 - 2019

KORKUSUZ P., ÖZKAVUKCU İ. S., YERSAL N., ESENDAĞLI G., KÖSE S., Project Supported by Higher Education Institutions, Leptinin spermatogonyal kök hücre kriyoprezervasyonundaki etkisinin araştırılması, 2017 - 2018

KARAKOÇ D., DİNÇER H. A., Ermiş D. Y., ESENDAĞLI G., Horzum U., Project Supported by Higher Education Institutions, Meme kanserinin karaciğer metastazında karaciğer rezeksiyonunun immünolojik etkileri, 2017 - 2018

KARABULUT İ., DİNÇSOY A. B., TUNCER M., CANSARAN DUMAN D., ESENDAĞLI G., YÖYEN ERMİŞ D., ZEYBEK N. D., Project Supported by Higher Education Institutions, 4T1 Hücreleriyle Farelerde Oluşturulan Meme Karsinomu Üzerine Usnik Asit Sekonder Metabolitinin in vivo Etkileri, 2017 - 2018

ESENDAĞLI G., Tavukçuoğlu E., Project Supported by Higher Education Institutions, PDL2 kostimülator molekülünü ifade eden akut miyeloid lösemi hücrelerinin yardımcı T hücre aktivasyonuna etkisi, 2017 - 2018

GÜRSOY R. N., TİMUR S. S., ESENDAĞLI G., Project Supported by Higher Education Institutions, Meme Kanseri Tedavisinde Aktif Hedeflendirme Amacıyla Kullanılmak Üzere Nano Boyutlu İlaç Taşıyıcı Sistemlerin Nanofarmasötikler Tasarımı ve in vitro Değerlendirilmesi, 2017 - 2018

ESENDAĞLI G., KURŞUNEL M. A., Project Supported by Higher Education Institutions, MD ANDERSON Kanseri Enstitüsü tarafından düzenlenen Global Academic Program 2017 Kongresine Katılım, 2017 - 2017

ESENDAĞLI G., ÜNER A., KURŞUNEL M. A., Project Supported by Higher Education Institutions, B lenfoma hücrelerinde B7 ailesi kostimülator moleküllerin araştırılması ve T hücre aktivasyonuna ve yorulmasına etkileri, 2016 - 2017

ESENDAĞLI G., Project Supported by Higher Education Institutions, CXCL KEMOKİNLERDEN TÜREVLENEN İMMÜNMODÜLATÖR PEPTİTLER, 2016 - 2017

ESENDAĞLI G., Project Supported by Higher Education Institutions, Miyeloid lösemi hücrelerinden kaynaklanan kostimülator sinyaller CD4 T hücrelerde fonksiyonel tükenmeye neden olur, 2016 - 2016

ESENDAĞLI G., Karaşar P., Project Supported by Higher Education Institutions, Yardımcı T hücre yanıtları bazalbenzeri meme kanseri hücreleri tarafından devam ettirilir ve PD1 ligandlarının artışı ile immün düzenlenmesini sağlar, 2015 - 2016

ESENDAĞLI G., Özkazanç D., Project Supported by Higher Education Institutions, Uyarılabilen kostimülator ligand (ICOS-LG) eksprese eden akut miyeloid lösemi (AML) hücrelerinin T lenfosit aktivasyonuna ve yorulmasına etkisi, 2015 - 2016

ESENDAĞLI G., Project Supported by Higher Education Institutions, İmmünoterapi Amaçlı Deneysel Onkoloji Sistemlerinin Geliştirilmesi, 2014 - 2016

ESENDAĞLI G., TUBITAK Project, CXCL kemokin öncül dizilerinden türevlenen küçük peptid moleküllerinin immün düzenleyici etkisinin değerlendirilmesi, 2013 - 2016

ESENDAĞLI G., Project Supported by Higher Education Institutions, All-trans retinoik asit (ATRA) ve 1?,25-dihidroksivitamin D3 (vitamin D3) ile uyarılan akut miyeloid lösemi hücrelerinin T hücre yanıtları üzerine etkisi, 2014 - 2015

## Metrics

Publication: 171

Citation (WoS): 1884

Citation (Scopus): 1266

H-Index (WoS): 24

H-Index (Scopus): 21